MCID: PRS040
MIFTS: 76

Prostate Cancer malady

Cancer category

Summaries for Prostate Cancer

Sources:
34MedlinePlus, 3CDC, 46Novus Biologicals, 64Wikipedia, 47OMIM, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MedlinePlus:34 The prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, being african-american, and some genetic changes. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (psa). other tests include ultrasound, x-rays, or a biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute

MalaCards: Prostate Cancer, also known as prostate carcinoma, is related to adenocarcinoma and colorectal cancer. An important gene associated with Prostate Cancer is AR (androgen receptor), and among its related pathways are Integrated Breast Cancer Pathway and Glioma. The drugs cisplatin and cisplatin pwdr and the compounds testosterone and serine have been mentioned in the context of this disorder. Related mouse phenotypes are cellular and reproductive system.

CDC:3 Prostate cancer is the most common cancer among American men. Most prostate cancers grow slowly, and don’t cause any health problems in men who have them.

Novus Biologicals:46 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

Wikipedia:64 Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive... more...

Description from OMIM:47 176807

Aliases & Classifications for Prostate Cancer

Sources:
8Disease Ontology, 9diseasecard, 20GeneTests, 22GTR, 47OMIM, 10DISEASES, 45Novoseek, 34MedlinePlus, 31LifeMap Discovery™, 61UMLS, 57SNOMED-CT, 40NCIt, 35MeSH, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer


Aliases & Descriptions:

prostate cancer 8 9 47 10 45 34 31
prostate carcinoma 8 45 61
malignant tumor of prostate 8 22
carcinoma of prostate 8 20
prostatic neoplasms 45 61
malignant tumor of the prostate 8
malignant neoplasm of prostate 61
ngp - new growth of prostate 8
tumor of the prostate 8
neoplasm of prostate 8
malignant neoplasms 61
prostatic neoplasm 8
cancer of prostate 8
prostate neoplasm 8
prostatic cancer 8


Related Diseases for Prostate Cancer

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Prostate Cancer family:

familial prostate cancer prostate cancer 1
prostate cancer 4 prostate cancer 3

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 482)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma30.9BRCA2, AR, CHEK2, CDH1, CD82, MXI1
2colorectal cancer30.8BRCA2, CHEK2, CDH1, CD82, EPHB2, PTEN
3gynecomastia30.8BRCA2, AR, SRD5A2
4male breast cancer30.7BRCA2, AR
5adenoma30.6EPHB2, CD82, CDH1
6bilateral breast cancer30.3CHEK2, BRCA2
7wilms tumor30.3BRCA2
8bladder carcinoma30.1CD82, CDH1
9hepatitis c30.1RNASEL
10stomach cancer29.9BRCA2, CHEK2, CDH1, CD82, EPHB2, ZFHX3
11ductal carcinoma in situ29.8CDH1, BRCA2
12familial colorectal cancer29.8PTEN, BRCA2
13prostate cancer 111.1
14vascular cancer11.0
15familial prostate cancer11.0
16hypoxia10.9
17prostate cancer 310.8
18somatostatin analog10.7
19bone marrow cancer10.7
20cancer progression/metastasis10.6
21radiation induced cancer10.6
22proctitis10.5
23prostate cancer, somatic10.5
24prostate cancer 410.5
25radiation proctitis10.5
26nasopharynx carcinoma10.5
27osteoporosis10.5
28oral cancer10.5
29chronic fatigue syndrome10.5
30testicular cancer10.4
31solitary fibrous tumor10.4
32urethra cancer10.4
33pituitary apoplexy10.4
34alopecia10.4
35prostate cancer, progression and metastasis of10.4
36acute leukemia10.4
37vaccinia10.3
38insulin resistance10.3
39benign prostate phyllodes tumor10.3
40extragonadal germ cell tumor10.3
41spinal cancer10.3
42urethral stricture10.3
43epiglottis cancer10.3
44acute lymphoblastic leukemia, childhood10.3
45intrahepatic gall duct cancer10.3
46neuroendocrine carcinoma10.3
47xeroderma pigmentosum10.3
48priapism10.3
49hypercalcemia10.3
50brain cancer10.3

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to prostate cancer

Clinical Features for Prostate Cancer

Sources:
47OMIM
See all sources

Clinical features from OMIM:

176807

Clinical synopsis from OMIM:

176807

Drugs & Therapeutics for Prostate Cancer

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 31LifeMap Discovery™, 61UMLS, 41NDF-RT
See all sources

Genetic Tests for Prostate Cancer

Sources:
20GeneTests, 22GTR
See all sources

Genetic tests related to Prostate Cancer:

id Genetic test Affiliating Genes
1 Prostate Cancer20 SRD5A2
2 Malignant Tumor Of Prostate22

Anatomical Context for Prostate Cancer

Animal Models for Prostate Cancer or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

MGI Mouse Phenotypes related to Prostate Cancer:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538412.7AR, SYT7, CHEK2, CDH1, EPHB2, RNASEL
2MP:000538912.4PTEN, BRCA2, SYT7, CDH1, EPHB2, ZFHX3
3MP:000200612.1BRCA2, AR, CHEK2, CDH1, ZFHX3, MXI1
4MP:000537911.2BRCA2, ZFHX3, MXI1, SRD5A2

Publications for Prostate Cancer

Sources:
51PubMed
See all sources

Articles related to Prostate Cancer:

(show top 50)    (show all 10938)
idTitleAuthorsYear
1
Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. (23180681)
2013
2
Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. (24089460)
2013
3
Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer. (21471764)
2011
4
Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. (19811499)
2010
5
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. (20418948)
2010
6
Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3. (19626590)
2010
7
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. (20145136)
2010
8
Synergetic bitherapy in mice with xenografts of human prostate cancer using a methional mimic (METLICO) and an aldehyde dehydrogenase 3 inhibitor (MATE): systemic intraperitoneal (IP) and targeted intra-tumoral (IT) administration. (19355878)
2009
9
PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. (18942118)
2009
10
Effect of laminin tyrosine-isoleucine-glycine-serine-arginine peptide on the growth of human prostate cancer (PC-3) cells in vitro. (19577562)
2009
11
IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis. (17719815)
2008
12
Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. (18384530)
2008
13
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. (18593621)
2008
14
The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. (18958175)
2008
15
Expression and prognostic relevance of annexin A3 in prostate cancer. (18222597)
2008
16
Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. (18358509)
2008
17
Transcription factor and microRNA regulation in androgen-dependent and -independent prostate cancer cells. (18831788)
2008
18
Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. (18701471)
2008
19
Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. (17929268)
2007
20
The role of PTEN in prostate cancer cell tropism to the bone micro-environment. (17347137)
2007
21
A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. (17903305)
2007
22
Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. (16983336)
2007
23
Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. (17875724)
2007
24
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. (17942943)
2007
25
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. (16796694)
2006
26
Effects of gamma-radiation on cell growth, cycle arrest, death, and superoxide dismutase expression by DU 145 human prostate cancer cells. (16470310)
2006
27
Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. (16869958)
2006
28
Antitumor effect of antisense ODC adenovirus on human prostate cancer cells. (16103892)
2005
29
An unusual gene dosage effect of p27kip1 in a mouse model of prostate cancer. (15701964)
2005
30
Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. (16140939)
2005
31
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. (15734963)
2005
32
Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. (15932919)
2005
33
The androgen receptor: a potential target for therapy of prostate cancer. (15013685)
2004
34
Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. (15217948)
2004
35
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. (14744778)
2004
36
Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men. (15162826)
2004
37
Bone morphogenetic protein signaling in prostate cancer cell lines. (14689587)
2004
38
Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer. (12660456)
2003
39
Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. (12727822)
2003
40
Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. (12853799)
2003
41
Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. (12213285)
2002
42
Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCalpha. (11584014)
2002
43
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. (11555613)
2001
44
STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. (10617865)
2000
45
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. (10465403)
1999
46
Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. (9809035)
1998
47
Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. (9074908)
1997
48
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. (9146612)
1997
49
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. (9815624)
1997
50
Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. (9294620)
1997

Genetic Variations for Prostate Cancer

Sources:
63UniProtKB/Swiss-Prot
See all sources

Genetic disease variations for Prostate Cancer:

63 (show all 21)
id Symbol AA change Variation SNP ID
1CHEK2p.Arg180CysVAR_019103rs77130927
2CHEK2p.Arg181CysVAR_019104rs137853010
3CHEK2p.Arg181HisVAR_019105rs121908701
4CHEK2p.Glu239LysVAR_019106
5CHEK2p.Glu64LysVAR_019107
6CHEK2p.Arg145ProVAR_019108
7CHEK2p.Gly167ArgVAR_019109
8CHEK2p.Arg180HisVAR_019110rs137853009
9CHEK2p.Ile251PheVAR_019111
10CHEK2p.Arg318HisVAR_019112rs143611747
11CHEK2p.Thr323ProVAR_019113
12CHEK2p.Tyr327CysVAR_019114
13CHEK2p.Thr476LysVAR_019115
14EPHB2p.Arg199HisVAR_032853
15EPHB2p.Ala279SerVAR_032854rs35882952
16EPHB2p.Val650AlaVAR_032855rs142173175
17EPHB2p.His679AsnVAR_032856
18EPHB2p.Met883ValVAR_032857
19EPHB2p.Ile909MetVAR_032858
20MXI1p.Glu152AlaVAR_004499
21PTENp.Met134LeuVAR_007469

Expression for genes affiliated with Prostate Cancer

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Prostate Cancer

Search GEO for disease gene expression data for Prostate Cancer.

Pathways for genes affiliated with Prostate Cancer

Sources:
38NCBI BioSystems Database, 30KEGG, 12EMD Millipore
See all sources

Pathways related to Prostate Cancer according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
111.7CHEK2, CDH1, PTEN, BRCA2, AR
2
Hide members
11.7PTEN, SRD5A2, CDH1, AR, BRCA2
311.7BRCA2, AR, CHEK2, CD82, PTEN
411.5PTEN, AR, BRCA2, CDH1
5
Hide members
11.2CHEK2, PTEN, AR
6
Transcription Androgen Receptor nuclear signaling
Hide members
11.2AR, SRD5A2, PTEN
7
Hide members
11.2CHEK2, CD82, PTEN

Compounds for genes affiliated with Prostate Cancer

Sources:
45Novoseek, 60Tocris Bioscience, 11DrugBank, 24HMDB, 50PharmGKB, 29IUPHAR, 2BitterDB
See all sources

Compounds related to Prostate Cancer according to GeneCards/GeneDecks:

(show all 21)
idCompoundScoreTop Affiliating Genes
1testosterone45 60 11 2415.5KLK15, BRCA2, AR, CDH1, RNASEL, SRD5A2
2serine4512.4KLK15, AR, CHEK2, CDH1, EPHB2, PTEN
3arginine4512.2AR, CDH1, EPHB2, RNASEL, SRD5A2, PTEN
4retinoic acid45 2413.2BRCA2, AR, CHEK2, CDH1, EPHB2, PTEN
5etoposide45 50 60 1115.0BRCA2, AR, CHEK2, CDH1, PTEN
6paraffin4512.0BRCA2, AR, CDH1, CD82, PTEN
7genistein45 29 60 2 11 2417.0BRCA2, AR, CHEK2, CDH1, PTEN
8progesterone45 60 29 11 2415.9BRCA2, AR, CDH1, SRD5A2, PTEN
9indole-3-carbinol4511.8PTEN, CDH1, AR, BRCA2
10adenine45 11 2413.8SRD5A2, RNASEL, CDH1, AR
11tamoxifen45 50 29 1114.7PTEN, CDH1, AR, BRCA2
12vitamin d4511.7PTEN, SRD5A2, CDH1, AR
13rapamycin4511.7AR, CHEK2, CDH1, PTEN
14steroid4511.6KLK15, BRCA2, AR, SRD5A2
15doxorubicin45 50 1113.6PTEN, CDH1, CHEK2, AR
16dutasteride45 1112.2SRD5A2, AR
17troglitazone45 29 60 1114.2AR, CDH1, PTEN
18sodium bisulfite4511.0AR, CDH1
19finasteride45 60 11 2414.0SRD5A2, AR
20docetaxel45 50 60 1113.9AR, CDH1, BRCA2
21adriamycin4510.6CHEK2

GO Terms for genes affiliated with Prostate Cancer

Sources:
16Gene Ontology
See all sources

Cellular components related to Prostate Cancer according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1Schmidt-Lanterman incisureGO:04322011.0PTEN, CDH1

Biological processes related to Prostate Cancer according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of axonogenesisGO:05077111.0PTEN, EPHB2
2prostate gland growthGO:06073610.9PTEN, AR
3dendritic spine morphogenesisGO:06099710.7PTEN, EPHB2

Products for genes affiliated with Prostate Cancer

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Prostate Cancer

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet